REG - BiVictriX Therapcts. - Appointment of Non-Executive Director

Bivictrix TherapeuticsAnnouncement

17/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220117:nRSQ5607Ya&default-theme=true

RNS Number : 5607Y  BiVictriX Therapeutics PLC  17 January 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

BiVictriX Appoints Dr Michael Kauffman as Non-Executive Director

Alderley Park, 17 January 2022 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, today announces that it has appointed Dr Michael Kauffman, M.D.,
Ph.D. to its Board of Directors as an Independent Non-Executive Director with
immediate effect.

 

Dr Kauffman joins the BiVictriX Board with more than 20 years of experience in
the life sciences industry, including expertise in preclinical research,
clinical development, and regulatory strategy. He currently serves on the
Boards of Karyopharm Therapeutics Inc ("Karyopharm"), Verastem Oncology, Kezar
Life Sciences and Adicet Bio. After co-founding Karyopharm, Dr Kauffman served
as Chief Executive Officer for over a decade, during which time he guided the
company from a discovery stage biotechnology company to a commercial stage
organisation and, most recently, transitioned into the role of Senior Clinical
Advisor. Prior to joining Karyopharm, Dr Kauffman was Chief Medical Officer of
Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. and, before that, was
President and Chief Executive officer of EPIX Pharmaceuticals, Inc.
(previously Predix Pharmaceuticals, Inc.). At Millennium Pharmaceuticals, Dr
Kauffman led the development programme for Velcade(®), a first-line treatment
for patients with multiple myeloma. He has also held a number of senior
positions at Millennium Predictive Medicine and Biogen. Dr Kauffman received
his M.D. and Ph.D. from the Johns Hopkins University School of Medicine and is
board certified in Internal Medicine.

Iain Ross, Chairman of BiVictriX, commented: "We are delighted to welcome Dr
Kauffman to the  BiVictriX Board. He brings a wealth of expertise in oncology
drug development, having been instrumental in the approval of several oncology
therapeutics. We look forward to working with him to advance the development
of our Bi-Cygni® therapeutics, where his proven corporate experience and
extensive network will be invaluable."

 

AIM Disclosures

The following information regarding the appointment of Dr. Michael Glen
Kauffman (aged 58) is required to be disclosed under Schedule 2(g) of the AIM
Rules for Companies:

 Current Directorships         Previous Directorships within the last five years
 Karyopharm Therapeutics Inc.  Infinity Pharmaceuticals Incorporated
 Verastem Oncology Inc.
 Kezar Life Sciences Inc.
 Adicet Bio Inc.

 

There are no further disclosures to be made under Schedule 2g of the AIM Rules
for Companies.

 

   For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Iain Ross, Chairman                                Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)  Tel: +44 (0) 20 3470 0470
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)         Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Genevieve Wilson, Alex Gunter   Tel: +44 (0) 20 3709 5700

                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of cancer indications including Diffuse Large
B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic
Cell Neoplasm. The Company is using these novel "twin-antigens" to develop
more effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFZGMMMVMGZZZ